A Study of DT2216 in Relapsed/Refractory Malignancies
NCT04886622
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Hematologic Malignancy
Interventions
DRUG:
DT2216
Sponsor
Dialectic Therapeutics, Inc